Pharmacokinetics of Morphine and Its Metabolites in Infants and Young Children After Congenital Heart Surgery
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 1
Abstract
The objective of this study was to characterize morphine glucuronidation in infants and children following cardiac surgery for possible treatment individualization in this population. Twenty children aged 3 days to 6 years, admitted to the cardiovascular intensive care unit after congenital heart surgery, received an intravenous (IV) loading dose of morphine (0.15 mg/kg) followed by subsequent intermittent IV bolus doses based on a validated pain scale. Plasma samples were collected over 6 h after the loading dose and randomly after follow-up doses to measure morphine and its major metabolite concentrations. A population pharmacokinetic model was developed with the non-linear mixed effects software NONMEM. Parent disposition was adequately described by a linear two-compartment model. Effect of growth (size and maturation) on morphine parameters was accounted for by allometric body weight-based models. An intermediate compartment with Emax model best characterized glucuronide concentrations. Glomerular filtration rate was identified as a significant predictor of glucuronide formation time delay and maximum concentrations. Clearance of morphine in children with congenital heart disease is comparable to that reported in children without cardiac abnormalities of similar age. Children 1–6 months of age need higher morphine doses per kilogram to achieve an area under concentration–time curve comparable to that in older children. Pediatric patients with renal failure receiving morphine therapy are at increased risk of developing opioid toxicity due to accumulation of morphine metabolites.
Authors and Affiliations
Mohammed H. Elkomy, David R. Drover, Kristi L. Glotzbach, Jeffery L. Galinkin, Adam Frymoyer, Felice Su, Gregory B. Hammer
Keywords
Related Articles
- EP ID EP680823
- DOI 10.1208/s12248-015-9826-5
- Views 40
- Downloads 0
The role of halogen substitution in classical cannabinoids: A CB1 pharmacophore model
The presence of halogens within the classical cannabinoid structure leads to large variations in the compounds' potencies and affinities for the CB1 receptors. To explore the structure activity relationships within this...
Statistical Power Calculations for Mixed Pharmacokinetic Study Designs Using a Population Approach
Simultaneous modelling of dense and sparse pharmacokinetic data is possible with a population approach. To determine the number of individuals required to detect the effect of a covariate, simulation-based power calculat...
Issues and Challenges of Subvisible and Submicron Particulate Analysis in Protein Solutions
The online version of this article (doi:10.1208/s12248-012-9335-8) contains supplementary material, which is available to authorized users.
Cellular uptake and concentrations of tamoxifen upon administration in poly(ε-caprolactone) nanoparticles
Purpose: In an attempt to increase the local concentration of tamoxifen in estrogen receptor positive breast cancer cells, we have prepared and characterized poly (ε-caprolactone) (PCL) nanoparticle formulation....
FDA Critical Path Initiatives: Opportunities for Generic Drug Development
FDA’s critical path initiative documents have focused on the challenges involved in the development of new drugs. Some of the focus areas identified apply equally to the production of generic drugs. However, ther...